Acarix AB (Malmö, Sweden) and Acarix A/S (Lyngby, Denmark) is a medical device company bringing cardiac screening tools to the GP’s practice. The company’s lead product is an advanced acoustic sensor. The device, which is attached to the patient’s chest, can – in a matter of five minutes – identify patients with coronary artery disease and therefore at risk of having a heart attack. In the western world, a heart attack is the most common cause of death, and 25% of all heart attacks happen without warning. The company started its commercial activities in 2Q 2017 in Germany.
Acarix AB is listed on NASDAQ Stockholm.